Gerald L. Andriole, Jr., MD, presented “Updates in Screening: Prostate Cancer Guidelines” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Andriole, Gerald L. “Updates in Screening: Prostate Cancer Guidelines” August 10th, 2020. Accessed Apr 2026. https://grandroundsinurology.com/updates-in-screening-prostate-cancer-guidelines/
Summary:
Gerald L. Andriole, Jr., MD, a Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri, reviews guidelines for prostate cancer screening, including the unchanged 2018 AUA guidelines and the 2020 updates to the NCCN and EAU guidelines. Following this, he explains why he disagrees with a 2020 article that suggests physicians use a PSA level of 10 ng/mL as the threshold when referring PCa patients to urology and thus biopsy. Lastly, he outlines five ways physicians can improve the early detection of prostate cancer.
For more on genomics and biomarkers for prostate cancer, visit our learning center.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Andriole presented this lecture during this year’s virtual conference in August 2020.
ABOUT THE AUTHOR
Gerald L. Andriole, Jr., MD, is the Chief Medical Officer of Prostatype Genomics AB in St. Louis, Missouri. Dr. Andriole is an internationally recognized key opinion leader in urology with a significant focus on prostate cancer. His research and clinical experience, much of which focuses on genomic testing, allows him to continue to positively impact the quality of care and outcomes for patients diagnosed with prostate cancer.
